文献速递造血干细胞移植与细胞治疗

伊布替尼治疗激素难治性慢性移植物抗宿主病:一项多中心真实世界分析

Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis.
PubMed 文献 · Blood Adv · 2025-01-01

该多中心回顾性研究纳入19个中心270例激素难治性慢性移植物抗宿主病患者,评估伊布替尼在美国食品药品监督管理局批准后的疗效。可评估患者6个月美国国立卫生研究院总体缓解率为45%(部分缓解42%,完全缓解3%),中位缓解持续时间15个月,最佳总体缓解率56%。肝脏受累与6个月总体缓解率相关(多因素分析比值比5.49,95%置信区间2.3-14.2,P<.001)。

要点

  • 可评估患者6个月总体缓解率45%,其中部分缓解42%、完全缓解3%。
  • 中位缓解持续时间15个月,最佳总体缓解率56%,多数在1至3个月内达到。
  • 肝脏受累与6个月总体缓解率相关(比值比5.49,95%置信区间2.3-14.2,P<.001)。

核心结论

  • 这些数据支持伊布替尼在激素难治性慢性移植物抗宿主病中具有活性,并提供了与缓解和无失败生存相关因素的新见解,同时展示了与停药相关的毒性特征。

研究设计与样本

  • 多中心回顾性研究,标准收集19个中心共270例激素难治性慢性移植物抗宿主病患者数据。

主要发现

  • 受累器官包括皮肤75%、眼61%、口腔54%、关节/筋膜47%、胃肠道26%、肺27%、肝脏19%、生殖器7%及其他4.4%。
  • 美国国立卫生研究院严重程度为轻度5.7%、中度42%、重度53%;39%为重叠亚型;卡氏功能状态评分≥80%者占72%。
  • 泼尼松中位剂量0.21 mg/kg(范围0-2.27);伊布替尼在慢性移植物抗宿主病起病后中位18.2个月开始,治疗线数分布为二线26%、三线30%、四线21%、五线9.6%、六线10%、七线或以上1.2%。
  • 可评估患者6个月美国国立卫生研究院总体缓解率为45%(部分缓解42%,完全缓解3%),中位缓解持续时间15个月(范围1-46)。
  • 肝脏受累与6个月总体缓解率相关(多因素分析比值比5.49,95%置信区间2.3-14.2,P<.001);最佳总体缓解率56%,其中86%在1至3个月内达到。

关键数值与推荐

  • 中位随访存活者30.5个月,无失败生存率6个月为59%(53%-65%),12个月为41%(36%-48%)。
  • 多因素分析显示年龄增加(风险比1.01,95%置信区间1.0-1.02,P=.033)、基线泼尼松剂量较高(风险比1.92,95%置信区间1.09-3.38,P=.032)和肺受累(风险比1.58,95%置信区间1.1-2.28,P=.016)与较差的无失败生存相关。
  • 伊布替尼停药最常见原因为慢性移植物抗宿主病进展(44%)或毒性(42%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To examine the activity of ibrutinib in steroid-refractory chronic graft-versus-host disease (SR-cGVHD) after the US Food and Drug Administration approval, we conducted a multicenter retrospective study. Data were standardly collected (N = 270 from 19 centers). Involved organs included skin (75%), eye (61%), mouth (54%), joint/fascia (47%), gastrointestinal (GI) (26%), lung (27%), liver (19%), genital (7%), and others (4.4%). The National Institutes of Health (NIH) severity was mild in 5.7%, moderate 42%, and severe 53%. Thirty-nine percent had overlap subtype. Karnofsky performance status (KPS) was ≥80% in 72%. The median prednisone was 0.21 mg/kg (0-2.27). Ibrutinib was started at a median of 18.2 months after cGVHD onset and in earlier lines of therapy (second line, 26%; third, 30%; fourth, 21%; fifth, 9.6%; sixth, 10%; seventh or higher, 1.2%). Among evaluable patients, the 6-month NIH overall response rate (ORR; complete response [CR]/partial response [PR]) was 45% (PR 42%; CR 3%). The median duration of response was 15 months (range, 1-46). Liver involvement had association with 6-month ORR (multivariate [MVA] odds ratio, 5.49; 95% confidence interval [CI], 2.3-14.2; P < .001). The best overall response was 56%, with most (86%) achieving by 1 to 3 months. With a median follow-up for survivors of 30.5 months, failure-free survival (FFS) was 59% (53%-65%) at 6 months and 41% (36%-48%) at 12 months. On MVA, increased age (hazard ratio [HR], 1.01; 95% CI, 1.0-1.02; P = .033), higher baseline prednisone (HR, 1.92; 95% CI, 1.09-3.38; P = .032), and lung involvement (HR, 1.58; 95% CI, 1.1-2.28; P = .016) had worse FFS. Ibrutinib discontinuation was most commonly due to progressive cGVHD (44%) or toxicity (42%). These data support that ibrutinib has activity in SR-cGVHD, provide new insight into factors associated with response and FFS, and demonstrate the toxicity profile associated with discontinuation.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Pidala J, Kim J, Kalos D, et al. Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis. Blood Adv. 2025. PMID: 39454280. doi:10.1182/bloodadvances.2024014374

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。